SARTORIUS STEDIM BIOTECH |
Market Closed -
Other stock markets
|
After market 12:38:50 pm | |||
| 208.3 EUR | -0.19% |
|
208 | -0.17% |
| Apr. 23 | SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating | ZD |
| Apr. 22 | Sartorius Stedim: in the red with brokerage comments | CF |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 57.46 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -13.03% | 21.73B | B | ||
| -3.07% | 187B | C+ | ||
| -2.17% | 108B | C | ||
| -4.05% | 67.71B | A | ||
| +9.71% | 53.07B | B- | ||
| +15.76% | 47.36B | B- | ||
| +6.01% | 39.73B | B+ | ||
| +10.15% | 28.56B | A- | ||
| +1.39% | 26.55B | B | ||
| +15.97% | 25.13B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- DIM Stock
- Ratings Sartorius Stedim Biotech
